29/07/2026
The Philippine FDA's report on the seizure of approximately โฑ111.3 million worth of the alleged violative health products during the first half of 2026 reflects an increasingly proactive and intelligence-driven approach to regulatory enforcement.
For businesses operating in the pharmaceutical, medical device, food, cosmetics, healthcare, and life sciences sectors, this serves as an important reminder that regulatory compliance is no longer limited to obtaining the necessary licenses or product registrations.
It also requires continuous compliance throughout the product lifecycle, from manufacturing and importation to advertising, online selling, labeling, distribution, post-market surveillance, and internal compliance systems.
Regulatory enforcement continues to evolve alongside technology and changing market practices. As regulators strengthen their capabilities, organizations should likewise strengthen their internal governance, compliance programs, documentation, and risk management processes.
In today's regulatory environment, compliance should not be viewed merely as a legal obligation. It is an essential component of good corporate governance and sustainable business operations.
Manila, Philippines
Read the full post of the Philippine FDA here:
๐
๐๐ ๐๐๐๐๐๐๐๐
๐๐๐ ๐๐๐
๐๐๐๐๐๐๐๐, ๐๐๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐ ๐๐
๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐
Protecting the Filipino public extends beyond the evaluation and approval of health products. It also requires a vigilant regulatory system capable of identifying, investigating, and decisively acting against those who undermine public health through the manufacture, importation, distribution, and sale of unauthorized and violative products.
Through intelligence-driven operations and expanded regulatory presence across both physical and digital marketplaces, the FDA continues to reinforce consumer protection nationwide. Building on these initiatives, the FDA significantly intensified its enforcement operations during the first half of 2026, resulting in the seizure of violative health products with an estimated market value of โฑ111.3 million.
These accomplishments underscore the FDA's continuing transformation into a more proactive, intelligence-driven, and collaborative regulatory authority. Through strengthened enforcement operations, expanded inspections, and sustained partnerships across government, the Agency remains steadfast in safeguarding public health and protecting the public from the risks posed by unauthorized, counterfeit, and substandard health products.
๐๐๐๐ ๐ฉ๐๐ ๐ฟ๐๐ง๐๐๐ฉ๐ค๐ง'๐จ ๐๐๐ฃ๐๐ง๐๐ก ๐๐ฃ๐ ๐๐ช๐๐ง๐ฉ๐๐ง๐ก๐ฎ ๐๐๐ฅ๐ค๐ง๐ฉ ๐ค๐ ๐๐๐๐ ๐ฉ๐๐ง๐ค๐ช๐๐ ๐ฉ๐๐ ๐ก๐๐ฃ๐ ๐๐ฃ ๐ฉ๐๐ ๐๐ค๐ข๐ข๐๐ฃ๐ฉ.
